Cargando…

834. Clinical Outcomes with Carbapenem-Resistant Pseudomonas aeruginosa that Retain Susceptibility to Traditional Antipseudomonal β-lactams: Atlanta, 2016-2018

BACKGROUND: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) often results from multiple mechanisms, creating unique phenotypic patterns of resistance including retaining susceptibility to traditional antipseudomonal β-lactams: cefepime (FEP), ceftazidime (CAZ) and piperacillin-tazobactam (TZP). O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howard-Anderson, Jessica, Bower, Chris W, Smith, Gillian, Satola, Sarah W, Jacob, Jesse T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777627/ http://dx.doi.org/10.1093/ofid/ofaa439.1023

Ejemplares similares

Mortality in patients with carbapenem-resistant Pseudomonas aeruginosa with and without susceptibility to traditional antipseudomonal β-lactams
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

Relation between Resistance to Antipseudomonal β-Lactams and ampC and mexC Genes of Pseudomonas aeruginosa
por: Rezaei, Fatemeh, et al.
Publicado: (2016)

Antipseudomonal β-Lactams Resistance in Iran
por: Rabiei, Mohammad Mahdi, et al.
Publicado: (2020)

1425. Impact of Social Determinants on Racial Differences in Carbapenem-Resistant Enterobacteriaceae Incidence, Atlanta, 2012-2018
por: Smith, Gillian, et al.
Publicado: (2020)

Performance of Antipseudomonal β-Lactams on the Accelerate PhenoTest BC Kit against a Collection of Pseudomonas aeruginosa Isolates
por: Sikorski, Aaron, et al.
Publicado: (2021)

787. Clinical and Genomic Epidemiology of mcr-9 Containing Carbapenem-resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012-2017
por: Babiker, Ahmed, et al.
Publicado: (2021)

506. Urinary Catheters Are Associated with Progression from Bacteriuria to Invasive Infections in Patients with Carbapenem-Resistant Enterobacteriaceae, Metropolitan Atlanta, 2011–2017
por: Howard-Anderson, Jessica, et al.
Publicado: (2019)

2175. In vitro Potency of Ceftolozane/Tazobactam and Other Antipseudomonal β-Lactams Against P. aeruginosa
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2018)

Carbapenemase genes and mortality in patients with carbapenem-resistant Enterobacterales, Atlanta, Georgia, 2011–2020
por: Witt, Lucy, et al.
Publicado: (2023)

486. Epidemiology of Carbapenem-Resistant Pseudomonas aeruginosa Identified through the Emerging Infections Program (EIP), United States, 2016–2018
por: Grass, Julian E, et al.
Publicado: (2019)

Clinical and Genomic Epidemiology of mcr-9-Carrying Carbapenem-Resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012 to 2017
por: Babiker, Ahmed, et al.
Publicado: (2022)

Synergistic Antipseudomonal Effects of Synthetic Peptide AMP38 and Carbapenems
por: Rudilla, Héctor, et al.
Publicado: (2016)

Evaluation of the Empiric use of Levofloxacin in Combination with Antipseudomonal Β-Lactams for the Treatment of Pneumonia
por: Bachna, Jon, et al.
Publicado: (2017)

1219. Unfavorable Clinical Outcomes with Polymyxins Compared to Ceftolozane/Tazobactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

Clinical Outcomes of Antipseudomonal vs. Non-Antipseudomonal Therapy in Patients with Osteomyelitis
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

The Art of War with Pseudomonas aeruginosa: Targeting Mex Efflux Pumps Directly to Strategically Enhance Antipseudomonal Drug Efficacy
por: Avakh, Asiyeh, et al.
Publicado: (2023)

2269. Clinical Outcomes in Patients with Carbapenem-Non-Susceptible, β-Lactam-Susceptible Pseudomonas aeruginosa Infections
por: Gavaghan, Victoria M, et al.
Publicado: (2019)

1587. Comparative In Vitro Antipseudomonal Activity of Ceftolozane/Tazobactam Against Pseudomonas aeruginosa Isolates from Children with Cystic Fibrosis
por: Kanwar, Neena, et al.
Publicado: (2019)

Clinical review: Balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use
por: Slama, Thomas G
Publicado: (2008)

Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms
por: Skalweit, Marion J, et al.
Publicado: (2016)

504. Epidemiology of End-stage Renal Disease (ESRD) Patients with Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: Atlanta Metropolitan Area, 2012–2017
por: Hurd, Jacqueline M, et al.
Publicado: (2019)

Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
por: Lee, Su Young, et al.
Publicado: (2023)

1162. Epidemiology of Carbapenem-Resistant Pseudomonas aeruginosa Identified Through the Emerging Infections Program (EIP), United States, 2016–2017
por: Grass, Julian, et al.
Publicado: (2018)

CCM 83.4
Publicado: (1983)

125. Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations and Other b-lactam Agents
por: Castanheira, Mariana, et al.
Publicado: (2022)

Resistance of Animal Strains of Pseudomonas aeruginosa to Carbapenems
por: Haenni, Marisa, et al.
Publicado: (2017)

Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study
por: Terahara, Fumitaka, et al.
Publicado: (2019)

2125. Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations against Serine-Carbapenemase producing Carbapenem-Resistant Pseudomonas aeruginosa
por: Lee, Su Young, et al.
Publicado: (2023)

Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015
por: Walters, Maroya Spalding, et al.
Publicado: (2019)

Comparison of 30- and 90-Day Mortality Rates in Patients with Cultures Positive for Carbapenem-resistant Enterobacteriaceae and Acinetobacter in Atlanta, 2011–2015
por: Sexton, Mary Elizabeth, et al.
Publicado: (2017)

Spread of Carbapenem Resistance by Transposition and Conjugation Among Pseudomonas aeruginosa
por: van der Zee, Anneke, et al.
Publicado: (2018)

The Effect of Decreased Antipseudomonal Drug Consumption on Pseudomonas aeruginosa Incidence and Antimicrobial Susceptibility Profiles over 9 Years in a Lebanese Tertiary Care Center
por: El-Basst, Rima, et al.
Publicado: (2023)

Comparative efficacy and safety of antipseudomonal β-lactams for pediatric febrile neutropenia: A systematic review and Bayesian network meta-analysis
por: Tan, Xinmei, et al.
Publicado: (2021)

Piperacillin–Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies?
por: Aslan, Abdullah Tarık, et al.
Publicado: (2022)

Characterization of Pseudomonas aeruginosa with discrepant carbapenem susceptibility profile
por: Pragasam, Agila K., et al.
Publicado: (2016)

Distinctive Regulation of Carbapenem Susceptibility in Pseudomonas aeruginosa by Hfq
por: Sonnleitner, Elisabeth, et al.
Publicado: (2020)

β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
por: Glen, Karl A., et al.
Publicado: (2021)

2784. Rates of Susceptibility and Heteroresistance to Novel Antibiotic Combinations in Carbapenem-Resistant Enterobacterales Isolates - Emory Healthcare, 2016-2021
por: Lin, Christina K, et al.
Publicado: (2023)

3167 Evaluation of risk factors for progression from carbapenem-resistant Enterobacteriaceae bacteriuria to an invasive infection
por: Howard-Anderson, Jessica, et al.
Publicado: (2019)

Association between duration of antipseudomonal beta-lactam therapy and Clostridioides difficile infections in monomicrobial Enterobacterales bloodstream infections at an academic medical center
por: Hawkins, Audry M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bqe73736hmf8gceugv2vv903h0